secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001159036-25-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q1 revenue up 35% to $265M; raises FY25 guidance, announces $250M buyback
--------------------------------------------------------------------------------

- Q1 revenue $264.9M (+35% YoY); GAAP EPS $0.93 (+55%); non-GAAP EPS $1.11 (+41%).
- Raised 2025 guidance: revenue $1.2-1.28B (prev $1.15-1.225B), adj. EBITDA $790-840M, non-GAAP EPS $5.30-5.70.
- Announced new $250M share repurchase; completed first $250M ASR in March 2025.
- Filed patent infringement lawsuit against Merck over MDASE for subcutaneous Keytruda.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/0001159036-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/halo-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer